Editorial: Predictive Factors and Survival Outcome of Conversion Therapy for Unresectable Hepatocellular Carcinoma Patients Receiving Atezolizumab and Bevacizumab: Comparative Analysis of Conversion, Partial Response and Complete Response Patients

被引：1
|
作者：
Gorgulho, Joao [1 ]
von Felden, Johann [2 ]
机构：
[1] Univ Med Ctr Hamburg Eppendorf, Dept Med Oncol Hematol & Bone Marrow Transplantat, Hamburg, Germany
[2] Univ Med Ctr Hamburg Eppendorf, Dept Med Gastroenterol & Hepatol, Hamburg, Germany
来源：
ALIMENTARY PHARMACOLOGY & THERAPEUTICS | 2024年 / 60卷 / 10期
关键词：
D O I：
10.1111/apt.18296
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：1467 / 1468
页数：2
相关论文
共 50 条
  • [41] Inflammation-related nomogram for predicting survival of patients with unresectable hepatocellular carcinoma received conversion therapy
    Wu, Jia-Lin
    Luo, Jun-Yang
    Jiang, Zai-Bo
    Huang, Si-Bo
    Chen, Ge-Run
    Ran, Hui-Ying
    Liang, Qi-Yue
    Huang, Ming-Sheng
    Lai, Li-Sha
    Chen, Jun-Wei
    WORLD JOURNAL OF GASTROENTEROLOGY, 2023, 29 (20) : 3168 - +
  • [42] Inflammation-related nomogram for predicting survival of patients with unresectable hepatocellular carcinoma received conversion therapy
    Jia-Lin Wu
    Jun-Yang Luo
    Zai-Bo Jiang
    Si-Bo Huang
    Ge-Run Chen
    Hui-Ying Ran
    Qi-Yue Liang
    Ming-Sheng Huang
    Li-Sha Lai
    Jun-Wei Chen
    World Journal of Gastroenterology, 2023, (20) : 3168 - 3184
  • [43] Clinical Outcomes and Histologic Findings of Patients With Hepatocellular Carcinoma With Durable Partial Response or Durable Stable Disease After Receiving Atezolizumab Plus Bevacizumab
    Shen, Ying-Chun
    Liu, Tsung-Hao
    Nicholas, Alan
    Soyama, Akihiko
    Yuan, Chang-Tsu
    Chen, Tse-Ching
    Eguchi, Susumu
    Yoshizumi, Tomoharu
    Itoh, Shinji
    Nakamura, Noriaki
    Kosaka, Hisashi
    Kaibori, Masaki
    Ishii, Takamichi
    Hatano, Etsuro
    Ogawa, Chikara
    Naganuma, Atsushi
    Kakizaki, Satoru
    Cheng, Chih-Hsien
    Lin, Po-Ting
    Su, Yung-Yeh
    Chuang, Chien-Huai
    Lu, Li-Chun
    Wu, Chi-Jung
    Wang, Hung-Wei
    Rau, Kun-Ming
    Hsu, Chih-Hung
    Lin, Shi-Ming
    Huang, Yi-Hsiang
    Hernandez, Sairy
    Finn, Richard S.
    Kudo, Masatoshi
    Cheng, Ann-Lii
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (34)
  • [44] OPTIMAL MANAGEMENT OF ATEZOLIZUMAB PLUS BEVACIZUMAB THERAPY FOR PATIENTS WITH UNRESECTABLE HEPATOCELLULAR CARCINOMA FOCUSING ON THERAPEUTIC MODIFICATIONS
    Tokunaga, Takayuki
    Tateyama, Masakuni
    Kondo, Yasuteru
    Miuma, Satoshi
    Miyase, Shiho
    Tanaka, Kentaro
    Narahara, Satoshi
    Inada, Hiroki
    Kurano, Sotaro
    Yoshimaru, Yoko
    Nagaoka, Katsuya
    Watanabe, Takehisa
    Setoyama, Hiroko
    Tanaka, Yasuhito
    HEPATOLOGY, 2022, 76 : S1351 - S1352
  • [45] Early complete tumor response as a survival predictor in hepatocellular carcinoma patients receiving stereotactic body radiation therapy
    Wu, Qi-Qiao
    Chen, Yi-Xing
    Du, Shi-Suo
    Hu, Yong
    Yang, Ping
    Zeng, Zhao-Chong
    CLINICAL AND TRANSLATIONAL RADIATION ONCOLOGY, 2023, 39
  • [46] Downstaging Conversion Therapy in Patients With Initially Unresectable Advanced Hepatocellular Carcinoma: An Overview
    Sun, Hui-Chuan
    Zhu, Xiao-Dong
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [47] Pretreatment Modified Albumin-Bilirubin Grade Is an Important Predictive Factor Associated with the Therapeutic Response and the Continuation of Atezolizumab plus Bevacizumab Combination Therapy for Patients with Unresectable Hepatocellular Carcinoma
    Tanaka, Takashi
    Takata, Kazuhide
    Yokoyama, Keiji
    Fukuda, Hiromi
    Yamauchi, Ryo
    Fukunaga, Atsushi
    Shakado, Satoshi
    Sakisaka, Shotaro
    Hirai, Fumihito
    CURRENT ONCOLOGY, 2022, 29 (07) : 4799 - 4810
  • [48] Correlation of high serum interleukin-6 with clinical outcome and T cell response in patients with unresectable hepatocellular carcinoma treated with atezolizumab and bevacizumab.
    Chon, Hongjae
    Kim, Chan
    Yang, Hannah
    Cheon, Jaekyung
    Ha, Yeonjung
    Lee, Sung Hwan
    Kang, Beodeul
    Kim, Ilhwan
    Kim, Hyeyeong
    Lee, Won Suk
    Jung, Sanghoon
    Gaillard, Vince
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 596 - 596
  • [49] Impact of radiological response and pattern of progression on overall survival in patients with hepatocellular carcinoma treated by atezolizumab-bevacizumab
    Campani, Claudia
    Vallot, Ariane
    Ghannouchi, Haroun
    Allaire, Manon
    Evain, Manon
    Sultanik, Philippe
    Sidali, Sabrina
    Blaise, Lorraine
    Thabut, Dominique
    Ganne, Nathalie
    Wagner, Mathilde
    Sutter, Olivier
    Nault, Jean Charles
    JOURNAL OF HEPATOLOGY, 2023, 78 : S585 - S586
  • [50] Anti-PD-1 Autoantibody Predicts Survival of Patients With Hepatocellular Carcinoma Receiving Atezolizumab/ Bevacizumab
    Sasaki, Yuki
    Matsumoto, Kazuyuki
    Takaki, Akinobu
    Adachi, Takuya
    Takahara, Masahiro
    Ozato, Keita
    Takeuchi, Yasuto
    Sue, Masahiko
    Miyake, Nozomi
    Wada, Nozomu
    Onishi, Hideki
    Shiraha, Hidenori
    Oda, Takashi
    Tsutsumi, Koichiro
    Nouso, Kazuhiro
    Kariyama, Kazuya
    Hagihara, Hiroaki
    Moriya, Akio
    Otsuka, Motoyuki
    GASTRO HEP ADVANCES, 2024, 3 (08): : 1138 - 1147
12345